Company Filing History:
Years Active: 2023
Title: Fadi Badr: Innovator in Immuno-Oncology
Introduction
Fadi Badr is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of immuno-oncology, particularly through his innovative patents. With a total of 2 patents, Badr's work focuses on developing novel therapeutic approaches for cancer treatment.
Latest Patents
Fadi Badr's latest patents include a bispecific antibody designed for ICOS and PD-L1. This multispecific antibody is structured in an mAb2 format, incorporating an ICOS-binding Fab region and a PD-L1-binding Fcab region. The application of this antibody is particularly relevant in immuno-oncology, especially for the treatment of solid tumors. Additionally, Badr's work includes combination therapies that involve antibodies targeting other immune checkpoint molecules such as PD-1 and CTLA-4, alongside anti-ICOS and anti-PD-L1. Another significant patent involves FC binding fragments that comprise a PD-L1 antigen-binding site. This application relates to specific binding members that target programmed death-ligand (PD-L1), which are crucial in treating cancer, infectious diseases, and inflammatory conditions.
Career Highlights
Throughout his career, Fadi Badr has worked with notable companies in the biotechnology sector, including F-star Therapeutics, Inc. and Kymab Limited. His expertise in antibody development has positioned him as a key player in advancing therapeutic options for patients.
Collaborations
Fadi has collaborated with talented individuals such as Mihriban Tuna and Francisca Wollerton Van Horck. These partnerships have further enhanced his research and development efforts in the field of immunotherapy.
Conclusion
Fadi Badr's innovative work in the development of bispecific antibodies and other therapeutic agents marks him as a significant contributor to the field of immuno-oncology. His patents reflect a commitment to improving cancer treatment and addressing various health challenges.